Erratum: Menopausal hormone therapy use in 17 European countries during the last decade (Maturitas (2014) 79 (287-291) DOI: 10.1016/j.maturitas.2014.07.002);Menopausal hormone therapy use in 17 European countries during the last decade

Maturitas

Volumn 79, Issue 3, 2014, Pages 287-291

  Ameye, Lieveke ^a   Antoine, Caroline ^b   Paesmans, Marianne ^a   De Azambuja, Evandro ^a   Rozenberg, Serge ^b  

^a JULES BORDET INSTITUTE   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Change; Europe; Menopausal hormone therapy; Sales data; Use

Indexed keywords

ESTROGEN; GESTAGEN; PREGNANE DERIVATIVE; TIBOLONE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; GYNECOLOGIST; HORMONAL THERAPY; HUMAN; ISCHEMIC HEART DISEASE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MENOPAUSAL HORMONE THERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); ADVERSE EFFECTS; BREAST NEOPLASMS; CLINICAL TRIAL; COMPARATIVE STUDY; CORONARY DISEASE; DRUG EFFECTS; ESTROGEN THERAPY; EUROPE; HEALTH; MENOPAUSE; MIDDLE AGED; MULTICENTER STUDY; PULMONARY EMBOLISM; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STATISTICS AND NUMERICAL DATA; STROKE;

AGED; BREAST NEOPLASMS; CORONARY DISEASE; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; EUROPE; FEMALE; GLOBAL HEALTH; HUMANS; MENOPAUSE; MIDDLE AGED; NORPREGNENES; PROGESTINS; PULMONARY EMBOLISM; RISK FACTORS; STROKE;

EID: 84908479036     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2015.02.004     Document Type: Erratum

References (29)

1. J.E. Rossouw, G.L. Anderson, and R.L. Prentice Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health initiative randomized controlled trial J Am Med Assoc 288 2002 321 333
2. G.L. Anderson, R.T. Chlebowski, and A.K. Aragaki Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial Lancet Oncol 13 May (5) 2012 476 486
3. M.L. Stefanick, G.L. Anderson, K.L. Margolis WHI Investigators Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy J Am Med Assoc 295 April (14) 2006 1647 1657
4. A.Z. LaCroix, R.T. Chlebowski, J.E. Manson WHI Investigators Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial J Am Med Assoc 305 April (13) 2011 1305 1314
5. S. Rozenberg, J. Vandromme, and C. Antoine Postmenopausal hormone therapy: risks and benefits Nat Rev Endocrinol 9 April (4) 2013 216 227
6. V. Beral Million Women Study Collaborators Breast cancer and hormone-replacement therapy in the Million Women Study Lancet 362 August (9382) 2003 419 427
7. V. Beral, G. Reeves, D. Bull, J. Green Million Women Study Collaborators Breast cancer risk in relation to the interval between menopause and starting hormone therapy J Natl Cancer Inst 103 February (4) 2011 296 305
8. C. Antoine, L. Ameye, M. Paesmans, and S. Rozenberg Systematic review about breast cancer incidence in relation to hormone replacement therapy use Climacteric October 2013 [Epub ahead of print]
9. A.G. Glass, J.V. Lacey Jr., J.D. Carreon, and R.N. Hoover Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status J Natl Cancer Inst 99 2007 1152 1161
10. P. De, C.I. Neutel, I. Olivotto, and H. Morrison Breast cancer incidence and hormone replacement therapy in Canada J Natl Cancer Inst 102 October (19) 2010 1489 1495
11. P.M. Ravdin, K.A. Cronin, and N. Howlader The decrease in breast-cancer incidence in 2003 in the United States N Engl J Med 356 2007 1670 1674
12. T.H. Keegan, E.T. Chang, and E.M. John Recent changes in breast cancer incidence and risk factor prevalence in San Francisco Bay area and California women: 1988 to 2004 Breast Cancer Res 9 2007 R62
13. A.S. Robbins, and C.A. Clarke Regional changes in hormone therapy use and breast cancer incidence in California from 2001 to 2004 J Clin Oncol 25 2007 3437 3439
14. A. Jemal, E. Ward, and M.J. Thun Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women Breast Cancer Res 9 3 2007 R28
15. V. Lundberg, H. Tolonen, B. Stegmayr, K. Kuulasmaa, K. Asplund WHO MONICA Project Use of oral contraceptives and hormone replacement therapy in the WHO MONICA project Maturitas 48 May (1) 2004 39 49
16. C. Antoine, L. Ameye, M. Paesmans, and S. Rozenberg Update of the evolution of breast cancer incidence in relation to hormone replacement therapy use in Belgium Maturitas 72 August (4) 2012 317 323
17. Eurobarometer health in the European Union 2007, September
18. European report OECD indicators - health at a glance 2011 69
19. A. Fournier, S. Mesrine, M.C. Boutron-Ruault, and F. Clavel-Chapelon Estrogen-progestogen menopausal hormone therapy and breast cancer: does delay from menopause onset to treatment initiation influence risks? J Clin Oncol 27 November (31) 2009 5138 5143
20. N. Colacurci, F. Fornaro, P. De Franciscis, M. Palermo, and W. del Vecchio Effects of different types of hormone replacement therapy on mammographic density Maturitas 40 November (2) 2001 159 164
21. J.M. Cline, T.C. Register, and T.B. Clarkson Effects of tibolone and hormone replacement therapy on the breast of cynomolgus monkeys Menopause 9 November-December (6) 2002 422 429
22. G. Ena, and S. Rozenberg Issues to debate on the Women's Health Initiative (WHI) study. Prescription attitudes among Belgian gynaecologists after premature discontinuation of the WHI study Hum Reprod 18 November (11) 2003 2245 2248
23. S.R. Cummings, B. Ettinger, P.D. Delmas LIFT Trial Investigators The effects of tibolone in older postmenopausal women N Engl J Med 359 August (7) 2008 697 708
24. P. Kenemans, N.J. Bundred, J.M. Foidart LIBERATE Study Group Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial Lancet Oncol 10 February (2) 2009 135 146
25. D.W. Sturdee, N. Panay International Menopause Society Writing Group Recommendations for the management of postmenopausal vaginal atrophy Climacteric 13 December (6) 2010 509 522
26. P.F. Harris, P.L. Remington, A. Trentham-Dietz, C.I. Allen, and P.A. Newcomb Prevalence and treatment of menopausal symptoms among breast cancer survivors J Pain Symptom Manage 23 June (6) 2002 501 509
27. A.R. Genazzani, H.P. Schneider, N. Panay, and E.A. Nijland The European Menopause Survey 2005: women's perceptions on the menopause and postmenopausal hormone therapy Gynecol Endocrinol 22 July (7) 2006 369 375
28. M.D. Dibonaventura, A. Chandran, M.A. Hsu, and A. Bushmakin Burden of vasomotor symptoms in France, Germany, Italy, Spain, and the United Kingdom Int J Womens Health 5 May 2013 261 269
29. R.E. Nappi, and M. Kokot-Kierepa Vaginal health: insights, views & attitudes (VIVA) - results from an international survey Climacteric 15 February (1) 2012 36 44